STOCK TITAN

Two Seas Reveals 135.5M-Share Position in Adaptimmune (ADAP)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Adaptimmune disclosure: Two Seas Capital entities and Sina Toussi report beneficial ownership of 135,484,206 ordinary shares of Adaptimmune, representing 8.5% of the outstanding share class. The holdings are held by Two Seas Global (Master) Fund LP and are represented by 22,580,701 American Depositary Shares. The filing states that Two Seas Capital has sole voting and sole dispositive power over these shares through its advisory and partnership roles; Two Seas Capital GP serves as general partner and Sina Toussi serves as Managing Member and chief investment officer. The 8.5% figure is calculated using a total of 1,590,309,546 shares outstanding.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Two Seas reports a material 8.5% stake (135.48M shares) in Adaptimmune with sole voting and dispositive power.

The Schedule 13G shows a material institutional position held in the Two Seas Global (Master) Fund LP and controlled via Two Seas Capital as investment adviser and Two Seas Capital GP as general partner. The position is represented by 22,580,701 ADS and is quantified against 1,590,309,546 shares outstanding. This is a routine disclosure of ownership and does not on its face indicate any change in control actions; it notifies investors of concentrated institutional ownership and voting control.

TL;DR: Reporting structure gives Two Seas sole voting/dispositive authority over an 8.5% block, a meaningful governance stake to monitor.

The filing identifies the reporting chain: Two Seas Capital LP (investment adviser) with Two Seas Capital GP LLC as general partner and Sina Toussi as Managing Member/CIO. All three report sole voting and dispositive power over the 135,484,206 shares held by the Global Fund. For governance analysis, the key facts are the sole control designation and the >5% threshold, both of which are material for shareholder vote influence and disclosure obligations.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Two Seas Capital LP
Signature:/s/ Sina Toussi
Name/Title:Sina Toussi / Managing Member of Two Seas Capital GP LLC, its General Partner
Date:08/13/2025
Two Seas Capital GP LLC
Signature:/s/ Sina Toussi
Name/Title:Sina Toussi / Managing Member
Date:08/13/2025
Sina Toussi
Signature:/s/ Sina Toussi
Name/Title:Sina Toussi / Self
Date:08/13/2025

FAQ

How many Adaptimmune (ADAP) shares does Two Seas Capital report owning?

135,484,206 ordinary shares, represented by 22,580,701 American Depositary Shares (as reported).

What percentage of ADAP does the reported position represent?

8.5% of the outstanding share class, calculated using 1,590,309,546 shares outstanding.

Does Two Seas have voting or dispositive power over these ADAP shares?

Yes — the filing reports sole power to vote and sole power to dispose of all 135,484,206 shares.

Which entities and individuals filed the Schedule 13G for ADAP?

Two Seas Capital LP, Two Seas Capital GP LLC, and Sina Toussi filed the statement on behalf of the Global Fund.

Where are the reporting entities organized and what roles do they play?

Two Seas Capital LP and Two Seas Capital GP LLC are organized in Delaware; Sina Toussi is a U.S. citizen who serves as Chief Investment Officer and Managing Member of the GP.
Adaptimmune Therapeutics Plc

NASDAQ:ADAP

ADAP Rankings

ADAP Latest News

ADAP Latest SEC Filings

ADAP Stock Data

14.55M
263.38M
0.63%
31.35%
9.49%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United Kingdom
ABINGDON, OXFORDSHIRE